UK Biomedical Cluster, Pfizer Partner to Translate Basic Science into Rare Disease Treatments | GenomeWeb

NEW YORK (GenomeWeb) – The Global Medical Excellence Cluster (GMEC), a UK non-profit focused on advancing translational research, has inked an agreement with Pfizer to use molecular and genomic technologies to develop medicines for treating rare diseases.

Under the five-year initiative, investigators at GMEC's partnering universities will work with Pfizer scientists in joint programs aiming to translate basic research into new drugs for treating rare diseases, GMEC said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.